Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake.

Autor:	Grémy O; CEA, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Université Paris-Saclay, Fontenay-aux-Roses, France., Blanchin N; CEA, Service de Santé au Travail, Saint-Paul-Lez-Durance, France., Miccoli L; CEA, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob, Université Paris-Saclay, Fontenay-aux-Roses, France.
Jazyk:	angličtina
Zdroj:	Health physics [Health Phys] 2021 Nov 01; Vol. 121 (5), pp. 494-505.
DOI:	10.1097/HP.0000000000001458
Abstrakt:	Abstract: In a worker who had internalized plutonium, most likely through inhalation of a somewhat soluble compound, an extensive diethylenetriaminepentaacetate (DTPA) treatment regimen was initiated several months after contamination. Numerous radiotoxicological analyses were performed in both fecal and urinary specimens collected, sometimes for three consecutive days after DTPA administration. Activity measurements showed the continued effectiveness of DTPA intravenous infusions in removing plutonium from tissues of retention even if the treatment regimen started very belatedly after contamination. In the present case, the activity excreted through urine within the first 24-h after a DTPA infusion contributed only about half of that activity excreted within the first three days (i.e., the cumulative activity of the first three 24-h urine collections). In addition, the careful study of the data revealed that DTPA-induced excretion of plutonium via fecal pathway significantly contributed to the overall decorporation. The intracellular chelation of plutonium may be responsible for this enhanced excretion of activity in feces as well as for the delayed and sustained increased clearance of activity in urine. The authors would suggest that the occupational physicians offer to individuals who internalized moderately soluble or soluble plutonium compounds undergo a long-term DTPA treatment, especially when it is not initiated promptly after intake. Under this scenario, measurements of plutonium in successive urine and fecal collections after treatment should be required to get a better estimate of the therapeutic benefit. Also, intracellular chelation and fecal route should be taken into account for better interpretation of radiotoxicological data and modeling of plutonium kinetics under delayed DTPA treatment. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Health Physics Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu